The Journal of dermatological treatment · 2025
Sex-disparities in pediatric and young adult patients with psoriasis treated with biologics: differences in adverse events and disease activity.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Gawahiri Malak, Barenbrug Liana, Bronkhorst Ewald M, de Jong Elke M G J, van den Reek Juul M P A, Seyger Marieke M B, BioCAPTURE Network, BioCAPTURE Network consists of
Аннотация
INTRODUCTION: Sex-differences in biological treatment outcomes in adult patients with psoriasis are well known. Potential sex-differences in a real-world cohort of pediatric and young adult patients with psoriasis using biologics were investigated in this study.
METHODS: Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.
RESULTS: We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.
CONCLUSION: Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.
METHODS: Data on pediatric (<18 years) and young adult (≥18 to ≤30 years) patients were obtained from the prospective, daily practice, ChildCAPTURE and BioCAPTURE registries. Drug survival and adverse event rates were compared between sexes. Confounder-corrected linear mixed models were used to compare Psoriasis Area and Severity Index (PASI) and (Children's) Dermatology Life Quality Index ((C)DLQI) scores between sexes.
RESULTS: We included 117 pediatric (65 females) and 243 young adult (124 females) patients on biologics (753.4 observation years). Young adult males had a significantly higher PASI at biologic initiation compared to females, with the same trend for pediatric patients. A higher adverse event rate was observed in females compared to males in both pediatric and young adult patients. Drug survival, PASI and (C)DLQI course during the first treatment year, were comparable between pediatric and young adult females and males.
CONCLUSION: Awareness on sex-differences (start PASI and adverse event rates) in pediatric and young adult patients with psoriasis is important for timely initiation and adjustment of appropriate treatment.